drugset
drugset / Trial / NCT04834440

Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

NCT04834440 ↗

Phase 4 Unknown 45 enrolled Healthpoint Hospital
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90)

Timeline

Start
2021-05-01
Primary completion
2021-09-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropivacaine Other / unclassified 15 ml Other

Indications

No indication recorded.